All In Biotech

Drug Trial Radar · NCT04628026

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

650

Planned (sponsor's estimate)

Start

Sep 13, 2022

Primary completion

Mar 2029

Study completion Feb 2032

Sponsor

Lead sponsor
University of UlmAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stichting Hemato-Oncologie voor Volwassenen Nederland
First posted
Nov 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Conditions

  • Acute Myeloid Leukemia

Interventions

  • VenetoclaxDrug

    Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy

  • PlaceboDrug

    Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy

  • Standard chemotherapyCombination product

    Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4 without daunorubicin. Consolidation chemotherapy with intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment.

  • Allogeneic stem cell transplantationOther

    Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free Survival (EFS)Time frame: 6 months/16 months after inclusion of last patient
  2. Frequency of dose-limiting toxicities (DLTs) during the observation period (Primary safety endpoint during dose-finding phase)Time frame: after cycle 1 (maximal day 42)

Locations

91 sites in 8 countries. Site status is shown where the registry gives one.

  • Tirol Kliniken GmbH

    Innsbruck, Austria · Not yet recruiting

  • Kepler Universitaetsklinikum GmbH

    Linz, Austria · Not yet recruiting

  • Ordensklinikum Linz GmbH

    Linz, Austria · Recruiting

  • Landeskrankenhaus (LKH) Rankweil, Interne E am Landeskrankenhaus Rankweil

    Rankweil, Austria · Recruiting

  • Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

    Salzburg, Austria · Not yet recruiting

  • Hanusch Krankenhaus Der Wiener Gebietskrankenkasse

    Vienna, Austria · Recruiting

  • Ziekenhuis Aan De Stroom

    Antwerp, Belgium · Not yet recruiting

  • Az St-Jan Brugge-Oostende A.V.

    Bruges, Belgium · Recruiting

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium · Recruiting

  • Katholieke Universiteit te Leuven

    Leuven, Belgium · Not yet recruiting

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium · Recruiting

  • CHU UCL NAMUR - Mont Godinne

    Yvoir, Belgium · Recruiting

  • North Estonia Medical Centre Foundation

    Tallinn, Estonia · Recruiting

  • Tartu University Hospital

    Tartu, Estonia · Recruiting

  • Helsinki University Central Hospital Meilahden Kolmiosairaala

    Helsinki, Finland · Recruiting

  • Tampere University Hospital

    Tampere, Finland · Not yet recruiting

  • Klinikum Aschaffenburg-Alzenau gGmbH

    Aschaffenburg, Germany · Recruiting

  • HELIOS Klinikum Bad Saarow GmbH

    Bad Saarow, Germany · Recruiting

  • Charité Berlin - Campus Mitte

    Berlin, Germany · Recruiting

  • Charité Berlin - Campus Benjamin Franklin

    Berlin, Germany · Recruiting

  • Charité Berlin - Campus Virchow Klinikum

    Berlin, Germany · Recruiting

  • Vivantes am Urban

    Berlin, Germany · Not yet recruiting

  • Vivantes Neukölln

    Berlin, Germany · Not yet recruiting

  • Vivantes Spandau

    Berlin, Germany · Withdrawn

  • Knappschaftskrankenhaus Bochum-Langendreer

    Bochum, Germany · Recruiting

  • Uniklinikum Bonn

    Bonn, Germany · Recruiting

  • Staedtisches Klinikum Braunschweig

    Braunschweig, Germany · Recruiting

  • Gesundheit Nord gGmbH Klinikverbund Bremen

    Bremen, Germany · Recruiting

  • Klinikum Darmstadt GmbH

    Darmstadt, Germany · Recruiting

  • St. Johannes Hospital Dortmund

    Dortmund, Germany · Recruiting

  • Marien Hospital Duesseldorf GmbH

    Düsseldorf, Germany · Withdrawn

  • Klinikum Frankfurt Hoechst GmbH

    Frankfurt, Germany · Recruiting

  • Justus-Liebig-Universitaet Giessen

    Giessen, Germany · Recruiting

  • Wilhelm-Anton-Hospital Goch

    Goch, Germany · Recruiting

  • Universitätsmedizin Greifswald

    Greifswald, Germany · Recruiting

  • Univeritätsklinikum

    Halle, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Asklepios Klinik Altona

    Hamburg, Germany · Recruiting

  • Asklepios Klinik St Georg

    Hamburg, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.